Web Analytics
Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%. | Deepscope News
MARKET

Select Market Data Region

Thailand Thailand United States United States
 April 13, 2026 10:52 PM  finance.yahoo.com Negative

Replimune Plans Layoffs After FDA Rejects Cancer Therapy Again. The Stock Craters 64%.

BMY REPL
Image

Shares of Replimune Group receive multiple downgrades after the Food and Drug Administration twice rejects its experimental cancer drug.

Continue Reading

Read original source

Top Watch

GOOG
GOOG
 NVDA
NVDA
 AUPH
AUPH
 GOOGL
GOOGL
 AAPL
AAPL
 SNDK
SNDK
 MU
MU
 CPRX
CPRX
 AVGO
AVGO
 OR
OR
ดูหุ้น US น่าสนใจวันนี้ ลองวางแผนลงทุน